Flashcards in Neurodegenerative Disease Deck (45):
1
Levodopa
Parkinsons
2
Levodopa MOA
metabolic precursor to Dopamine. Becomes dopamaine to restore post-synaptic concentration of dopamine. Activates post-synaptic D1 and D2 receptors
3
Carbidopa
inhibits dopa decarboxylase to allow levodopa to enter the BBB
4
Levodopa contraindications
MAOI use, history of malignant melanoma, narrow angle glaucoma. Monitor LFT
5
Levodopa ADR
Dyskinesias, "on-off" effect, Nausea, anorexia, hypotension, confusion, insomnia, nightmares, schizophrenic like syndrome
6
Dopamine Agonists
apomorphine, bromocriptine, pergolide, pramipexole, ropinirole, rotigotine
7
Dopamine Agonists ADR
N/V, anorexia, hypotension, cardiac arrythmias, HA, confusion, hallucinations, sedation, pulmonary fibrosis
8
Ergot Dopamine Agonists
Bromocriptine and Cabergoline. D2 receptor agonists
9
NonErgot Dopamine Agonists
Pramipexole, Ropinerole, Rotigotine (patch), Apomorphine
10
Pramipexole indications
advanced Parkinsons and restless leg syndrome
11
Ropinerole indications
monotherapy in mild parkinsons and restless leg syndrome
12
Rotigone ADR
sudden somnolence
13
Apomorphine receptor type
D1/D2
14
Pramipexole receptor type
D3. some D2/D4
15
Ropinerole receptor
D2
16
Apomorphine indications
subQ injection for temporary relief of "off" periods
17
Apormorphine ADR
dyskinesias, drowsiness, sweating, hypotension
18
Selegiline MOA
monoamine oxidase- B inhibitors
19
Selegiline indications
effective as monotherapy or in combination with levodopa for parkinsons. enables reduction in levodopa
20
Selegiline ADR
blocks MAO-A at high doses, fatal hyperthermia
21
Rasagiline MOA
irreversible MAO-B inhibitor
22
Rasagiline indications
early treatment of Parkinsons and as adjunct with Levodopa
23
Rasagiline metabolism
extensive liver metabolism. metabolized at CYP1A2.
24
Rasagiline Drug interactions
meperidine, dextramethorphan, St. Johns Wort, cyclobenzaprine, ciprofloxacin
25
Catechol-O-Methyltransferase inhibitors
Tolcapone, entecapone
26
COMT inhibitors MOA
inhibits metabolism of dopamine. increase availability of Ldopa
27
COMT indications
adjunct treatment for Parkinsons with levodopa
28
COMTI ADR
increased plasma concentration of Ldop (dyskinesias, nausea, confusion), Diarrhea, abd pain, orthostatic hypotension, sleep disorders, orange urine discoloration. Tolcapone may be hepatotoxic
29
COMT pearls
do not use MAO-A and COMT together. MAO-B may be okay. Entacapone=P450 inhibitor. Taper dosing for discontinuation
30
Stalevo
Levodopa + Carbidopa + entacapone
31
Amantadine
Antiviral drug with anti-parkinsonian properties
32
Amantadine ADR
primarily CNS- restlessess, depression, irritability, insomnia, agitation, excitement, hallucinations, confusion, seizures. HA, edema, postural hypotension, HF, GI
33
Anticholinergics MOA
dopamine def augment excitatory cholinergic system. blocks this system
34
Anitcholinergics
Trihexyphenidyl and Benztropine
35
AA of Neuro guidelines
Selegiline first, Levodopa or dopamine agonist, Alternative- exercise, speech therapy
36
Cholinesterase inhibitors Indications
First line in Alzheimers
37
Cholinesterase inhibitors
Donezepil, Rivastigmine, Galantamine
38
Donezepil ADR
Cholinergic side effects , NVD, insomnia, fatigue, muscle cramps
39
Donezepil interactions
metabolized by P450
40
Rivastigmine ADR
NVD and weight loss, dyspepsia, sinusitis, dizziness
41
Galantamine MOA
dual MOA. Competitive inhibition of acetylcholinesterase and allosteric modulation of presynaptic and postsynaptic nicotinic receptors
42
Galantamine ADR
N, weight loss, agitation and diarrhea
43
NMDA receptor Antagonists
Memantine
44
Memantine
noncompetitive NMDA receptor antagonist. increased glutamate release in CNS produces excitotoxic reactions and cell death, idea is to block this.
45